Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial.

ABSTRACT:

SUBMITTER: Haji Sadeghi M 

PROVIDER: S-EPMC12684106 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature